TD Asset Management
APRE icon

TD Asset Management’s Aprea Therapeutics APRE Stock Holding History

TD Asset Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-854
Closed -$411K – 1437
2020
Q3 		$411K Hold
854
– – ﹤0.01% 1287
2020
Q2 		$662K Buy
+854
New +$560K ﹤0.01% 1160

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

TD Asset Management's APRE Position: Q4 2020 in Review

TD Asset Management sold out of Aprea Therapeutics (APRE) in Q4 2020, closing a stake of 854 shares — an estimated $411K sold.

TD Asset Management first reported a position in APRE in Q2 2020 and held it in 2 quarters. The position peaked at $662K in Q2 2020. 66 funds tracked by Wall St. Rank hold APRE as of Q4 2020.

  • TD Asset Management reported no remaining Aprea Therapeutics position as of Q4 2020 after selling out during the quarter.
  • TD Asset Management sold 854 Aprea Therapeutics shares in Q4 2020, an estimated $411K.
  • TD Asset Management first reported a position in Aprea Therapeutics in Q2 2020 and held it in 2 quarters.
  • TD Asset Management's Aprea Therapeutics position peaked at $662K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2020.

Based on TD Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.